Highlights from

EAN 2020

European Academy of Neurology

Virtual 23 - 26 May 2020

Eptinezumab in chronic migraine and medication-overuse headache

In the pivotal PROMISE-2 study, eptinezumab was efficacious in patients with chronic migraine and medication-overuse headache (MOH). After 12 weeks, the eptinezumab group had a greater reduction in migraine days than the placebo group. Efficacy was noted from day 1 and sustained through 24 weeks [1].

In PROMISE-2, 1,072 chronic migraine patients participated, 431 of whom had a dual diagnosis of chronic migraine and MOH. Participants were randomised to eptinezumab 100 mg, 300 mg, or placebo for 2 intravenous doses administered every 12 weeks. Eptinezumab is an anti-calcitonin gene-related peptide monoclonal antibody. MOH patients were equally distributed in these 3 groups. During the 28-day baseline period, MOH patients experienced a mean 16.7 migraine days.

Efficacy of eptinezumab versus placebo on day 1 through 7 was lower with eptinezumab than placebo. On baseline, about 60% of participants experienced migraine; on day 1, this rate was 27.8% (100 mg); 30.1% (300 mg); and 45.5% (placebo). In all of the first 12 weeks of intervention, eptinezumab-treated patients experienced greater reductions in monthly migraine days (MMDs) than placebo patients (100 mg, -8.2; 300 mg, -8.5; placebo, -5.2). About twice as many patients in the eptinezumab groups were ≥50% (60.4%; 61.9%; 34.5%) or ≥75% migraine responders (27.3%; 29.9%; 14.5%). Results were similar during weeks 13-24.

Keywords: Migraine Disorders; Eptinezumab; PROMISE-2; Calcitonin Gene-Related Peptide

  1. Diener H-C, et al. Abstract EPR1090, EAN 2020.

Top image: @ iStockPhoto: koto_feja

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.